pembrolizumab as adjuvant therapy for tnbc
Published 1 year ago • 1K plays • Length 0:56Download video MP4
Download video MP3
Similar videos
-
1:42
the case for neoadjuvant pembrolizumab in tnbc
-
3:09
keynote-522: neoadjuvant and adjuvant pembrolizumab for early tnbc
-
4:20
keynote 522: pembrolizumab as neoadjuvant treatment for early tnbc
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
1:30
keynote-355: hrqol unaffected by the addition of pembrolizumab to chemotherapy for tnbc
-
3:26
chemo-immunotherapy for tnbc
-
1:30
emerging immunotherapy beyond checkpoint inhibitors for tnbc
-
5:21
optimal neoadjuvant and adjuvant therapy for patients with early tnbc
-
1:03
new directions in immunotherapy for improving outcomes in tnbc
-
1:32
treatment algorithm for tnbc
-
2:07
keynote-355: pembrolizumab in triple-negative breast cancer
-
1:01
chemo-immunotherapy for tnbc
-
1:03
remaining questions on the use of neoadjuvant pembrolizumab in early tnbc following keynote-522
-
0:41
recent advances in targeted therapies for tnbc
-
2:05
treatment advances in tnbc
-
2:16
tailoring neoadjuvant and adjuvant therapy in tnbc
-
1:34
strategies to improve the response to immunotherapy in tnbc
-
1:58
ascent-04: sacituzumab govitecan and pembrolizumab in pd-l1-positive tnbc
-
2:46
de-escalation of therapy in early-stage tnbc